On July 9, 2002, the principal investigators of the estrogen-progestin arm of the Women’s Health Initiative announced that they were halting the trial early because the data showed increased rates of breast cancer, cardiovascular events, and stroke in women receiving combined hormone therapy. The press conference reverberated through clinical practice with a force that few single research findings have matched in modern medicine. Within eighteen months, prescriptions for menopausal hormone therapy in the United States had fallen by more than half. They have never fully recovered. What the field has been doing in the intervening twenty-three years is reconstructing the clinical evidence with more nuance than the WHI’s binary headline permitted, while operating without the marketing infrastructure that previously sustained the category.
The WHI’s findings, in retrospect, were both robust and narrower than the public response treated them as being. The increased risks observed were principally in women who initiated hormone therapy more than ten years after the onset of menopause—a population for whom the underlying cardiovascular and cancer risks were already elevated by age. Subsequent reanalyses, including pre-specified subgroup analyses that the trial’s principal investigators conducted in the years after the initial publication, identified what has come to be called the timing hypothesis: hormone therapy initiated within ten years of menopause produces a different risk-benefit profile than therapy initiated later. The early use case, which is also the use case that addresses the symptoms women actually present with, may have considerably more favorable risk-benefit properties than the WHI headline suggested.
The clinical guidelines that have emerged over the past decade have begun to incorporate this nuance. The North American Menopause Society’s 2022 position statement, the most authoritative clinical guidance currently available, supports the use of menopausal hormone therapy in symptomatic women under age 60 or within ten years of menopause onset, with individualized consideration of cardiovascular and breast cancer risk factors. The guideline represents a substantial recalibration from the post-WHI default of hormone therapy avoidance. Whether prescribing patterns have followed the guideline is a separate question; the residual fear among both clinicians and patients has proved durable.
What complicates the contemporary HRT landscape is the proliferation of compounded bioidentical hormone preparations marketed as alternatives to FDA-approved hormone products. The marketing emphasizes the molecular identity of the compounded hormones with endogenous estradiol and progesterone—a true claim, but one that obscures the absence of the safety data that supports the FDA-approved alternatives. Several large compounding operations and telehealth platforms have built substantial businesses around bioidentical hormone therapy, often coupled with saliva testing protocols that have minimal clinical validity but considerable marketing appeal. The FDA has issued repeated warnings about specific marketing practices but has not, in any sustained way, addressed the underlying clinical practice of compounded bioidentical hormone prescribing.
The clinical safety question for compounded bioidenticals is genuinely uncertain. The molecules themselves are the same as in FDA-approved products, but the dosing, formulation, and quality control vary considerably across compounding pharmacies. The FDA-approved estradiol products carry the cardiovascular and breast cancer risks established by the WHI and subsequent trials; the compounded versions presumably carry similar risks but have not been specifically studied in trial populations. The clinical practice that has grown up around bioidentical hormones often substitutes saliva or urine testing for the standard serum estradiol monitoring used in FDA-approved hormone therapy, with the result that some patients are dosed to levels that produce serum estradiol concentrations far above physiologic ranges without their prescribing clinician recognizing it.
There is a separate clinical question about whether the post-WHI generation of menopausal women received inadequate symptom management for what was, in retrospect, a treatable condition. An NEJM perspective in 2022 noted that an entire cohort of women who reached menopause between roughly 2002 and 2015 had higher rates of vasomotor symptoms, sleep disruption, mood changes, and sexual dysfunction than would have been the case under more permissive prescribing patterns. The associated impacts on workforce participation, quality of life, and downstream health outcomes are difficult to quantify but probably substantial. Whether the WHI-driven prescribing collapse, in retrospect, did more harm than the prescribing patterns it replaced is a question the field has begun to ask uncomfortably.
The non-hormonal alternatives that have entered the menopausal symptom management space in recent years include fezolinetant, an NK3 receptor antagonist approved by the FDA in 2023 for vasomotor symptoms. The drug represents a different therapeutic mechanism—targeting the hypothalamic neurons that drive hot flashes rather than supplementing the hormones whose decline triggers them—and offers an option for women who cannot or will not take hormone therapy. Whether fezolinetant and similar emerging therapies will substitute for hormone therapy, complement it, or remain a niche option for specific patient populations is an open question. The early prescribing data suggests substantial uptake among clinicians who had been reluctant to prescribe hormones, but the long-term commercial trajectory is unclear.
The genitourinary syndrome of menopause—vaginal atrophy, urinary symptoms, sexual dysfunction—is a separate clinical entity that the post-WHI prescribing collapse affected in particularly unfortunate ways. Local vaginal estrogen, which produces minimal systemic absorption and has a fundamentally different risk profile from systemic hormone therapy, was caught up in the broader hormone avoidance pattern despite carrying essentially none of the systemic risks the WHI documented. ACOG and the menopause societies have spent years trying to communicate this distinction without much success at the patient level. The result is that millions of women experience genitourinary symptoms that have a safe, effective, FDA-approved treatment that they will not consider because of the WHI’s reputational shadow.
There is a generational dimension worth noting. The cohort of women now entering menopause—roughly Gen X and the older end of millennials—is more willing to discuss symptoms openly than previous cohorts were, more skeptical of clinical guidance that they perceive as paternalistic, and more likely to seek treatment through whatever channel is most accommodating. This combination has driven much of the contemporary growth in compounded bioidentical hormone prescribing and in the broader menopause-focused telehealth sector. Whether the conventional medical system will respond by absorbing this demand into evidence-based hormone therapy practices, or whether the parallel sector will continue to capture the patient base that conventional practice has not effectively engaged, depends on choices being made by individual clinicians, by health system administrators, and by medical education curricula that are only beginning to address the gaps in menopausal medicine training.
What the past two decades have produced is a peculiar clinical situation in which one of the most common physiological transitions in human life is treated, in clinical practice, with a level of variability and confusion that would not be tolerated in nearly any other area of medicine. BMJ commentary on menopause clinical practice variation in 2022 noted that prescribing rates for hormone therapy in symptomatic women varied by an order of magnitude across primary care practices in the same region, with no clear correlation to patient population or risk factors. The variation reflects, in part, the absence of clear consensus on the appropriate threshold for treatment. It also reflects, more uncomfortably, the persistence of clinical training gaps that have not been adequately addressed since the WHI disrupted the previous training paradigm.
What the field appears to be moving toward, slowly and unevenly, is a recalibrated default in which menopausal hormone therapy is offered to symptomatic women under appropriate criteria, prescribed at doses and durations supported by current clinical evidence, monitored through serum measurements rather than alternative testing of dubious validity, and discussed with patients in terms that acknowledge both the modest absolute risks and the substantial symptom benefits. The recalibration is happening too slowly for the women currently transitioning through menopause, who are in many cases left choosing between under-treatment in the conventional system and over-treatment in the parallel sector. Whether the field can complete the recalibration in time to serve the next cohort of menopausal women adequately depends on changes in medical education, clinical guideline communication, and the cultural narratives about hormone therapy that the WHI’s headline created and that the field has not yet been able to fully revise. Twenty-three years is a long time for a clinical course correction. There is no obvious mechanism by which it accelerates.
